1[1]Riveline JP, Danchin N, Ledru F, et al. Sulfonylureas and cardiovascular effects: from experimental data to clinical use.Available data in humans and clinical applications [J].Diabetes Metab,2003,29(3) :207.
2[2]Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience[J]. Clin Ther,2003,25 (3): 799.
3[3]Tsunekawa T, Hayashi T, Suzuki Y, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects [J]. Diabetes Care,2003,26(2) :285.
4[4]Haupt A, Kausch C, Dahl D, et al. Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide [J].Diabetes Care,2002,25(12) :2129.
5[5]Weitgasser R, Lechleitner M, Luger A, et al. Effects of glimepiride on HbA(1c) and body weight in type 2 diabetes: results of a 1.5-year follow-up study[J]. Diabetes Res Clin Pract,2003,61 (1): 13.
6[6]Simeonov SB, Botushanov NP, Iliev DA, et al. Amaryl (glimepiride) in patients with type 2 diabetes mellitus [J].Folia Med (Plovdiv), 2002,44 (3): 15.
7[7]Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors[J]. Clin Ther,2003,25(2):472.
8[8]Holstein A, Plaschke A, Hammer C, et al. Characteristics and time course of severe glimepiride- versus glibenclamideinduced hypoglycaemia [J]. Eur J Clin Pharmacol, 2003, 59(2):91.
5Miieller G, Hartz D, Punter J, Koh H,Akiyama, Yui K, et al. Differemial interacting of glimepiride with the beta cell sulfonylurea receptor [ J]. Biochim Bio - phys Acta, 2004 ; 1191 : 267 - 277.
6Koshiba K, Nomura M, Nakaya Y. et al. Efficacy of glimepiride on insulinresistance, adipocyto- kines, and atherosclerosis [ J ]. J Wed Invest,2006;53(2) :87 -94.
7Purrelo F., Rabuazza A.M. Metabolic factors that affect beta cell function and survival [J]. Diabetes Nutr Metab, 2000, 13(2): 8491.
8Sivitz W.L. Lipotoxicity and glucotoxicity in type 2 diabetes effects on developmentand progression [J]. Postgrad Med, 2001,109(d):55-59,63-64.
9Robertson R.P., Harmon J., Tran P.O., et al. Glucose toxicity in betacells: type 2 diabetes, good radicals gone bad, and the glutathione connection [J]. Diabetes, 2003, 52(3): 581587.
10Del Prato S., Marchetti P., Bonadonna R.C. Phasic insulin release and metabolic regulation in type 2 diabetes [J].Diabetes,2002,51 (supp.ll): 109-116.
